Results 231 to 240 of about 32,390 (296)

Right Ventricular Pulmonary Artery Coupling Ratio as a Predictor for Adverse Outcome in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Naveen Kumar, Bornali Dutta, Farhin Iqbal   +2 more
openalex   +1 more source

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source

Thymoquinone and aerobic exercise mitigate HFpEF-induced cardiac injury via Apaf1/Cycs axis regulation. [PDF]

Front Pharmacol
Pei Z, Gao S, Yang J, Liu C, Pan Y.
europepmc   +1 more source

V02max Determinants Are Associated With Different Cognitive Outcomes in Women With HFrEF and HFpEF

C. Gagnon, Florent Besnier, P.-É. Magnan, B. Bérubé, Floriane Sellier, Josep Iglésies, M Gayda, V. Dionne, H. Benhalima, Aruna Nigam, M. Juneau, P.L. L’Allier, Nadia Bouabdallaoui, Jean‐Lucien Rouleau, Louis Bherer   +14 more
openalex   +2 more sources

Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles

European Journal of Heart Failure, EarlyView.
Graphical overview of derivation and testing of multiparametric trajectories of cardiac function. This study identified six trajectories of LV systolic and diastolic function from mid‐ to late‐life. Predicted trajectory from single echocardiogram identified four trajectories at differential risk for HFpEF and HFrEF.
Anne Marie Reimer Jensen, James C. Ross, Victoria Arthur, Michael E. Hall, Kunihiro Matsushita, Brandon Lennep, Pamela L. Lutsey, Tor Biering‐Sørensen, Amil M. Shah   +8 more
wiley   +1 more source

Potential Implications of Body Mass Composition Changes in Heart Failure Patients in the Era of SGLT2i, GLP-1 RA, and GIP/GLP-1 RA. [PDF]

Pharmaceuticals (Basel)
Gryglewska-Wawrzak K, Kapłon-Cieślicka A, Pawlak A, Tomaszuk-Kazberuk A, Rubiś P, Niedziela J, Bielecka-Dąbrowa A.   +6 more
europepmc   +1 more source

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR‐Reduced

European Journal of Heart Failure, EarlyView.
Empagliflozin effects and heart failure outcomes in patients with heart failure with reduced ejection fraction and atrial fibrillation or sinus rhythm. AF, atrial fibrillation; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; SE, standard error ...
Michael Böhm, Javed Butler, Amr Abdin, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Martina Brueckmann, Anne Pernille Ofstad, Elke Schueler, Christoph Wanner, Faiez Zannad, Stefan D. Anker, Milton Packer, on behalf of the EMPEROR‐Reduced Trial Committees and Investigators   +13 more
wiley   +1 more source

The role of serum uric acid in survival prediction in patients with acute myocardial infarction accompanied by heart failure with preserved ejection fraction. [PDF]

Front Cardiovasc Med
Kim S, Lee KY, Kim KA, Byeon J, Shin S, Hwang BH, Kim JJ, Choo EH, Kim CJ, Kyoung Sa Y, Park MW, Hyun S, Yoon AH, Ahn Y, Chang K.   +14 more
europepmc   +1 more source

Low‐dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation – the RATE‐AF randomized trial

European Journal of Heart Failure, EarlyView.
Summary of the change in left ventricular systolic and diastolic parameters from baseline to 12 months in patients with permanent atrial fibrillation (AF) and a left ventricular ejection fraction (LVEF) ≥50%. P‐values indicate the significance of the adjusted mean difference of the parameters at 12 months between the beta‐blocker and digoxin arm. E/e′,
Karina V. Bunting, Asgher Champsi, Simrat K. Gill, Khalil Saadeh, A. John Camm, Mary Stanbury, Sandra Haynes, Jonathon N. Townend, Richard P. Steeds, Dipak Kotecha, on behalf of the RAte control Therapy Evaluation in Permanent Atrial Fibrillation (RATE‐AF) Trial Group   +10 more
wiley   +1 more source